New quarterly report expected Apr 21, 2026. Report will refresh after results.
I
Intuitive Surgical, Inc.
ISRG · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Owning the Surgeon's Hands at a Price That Owns You Back
The market correctly identifies this as a dominant, durable franchise — but it has already priced in every optionality bet at once, leaving no asymmetry for the buyer; the risk isn't that the business disappoints, it's that being right about the business still produces a poor investment outcome from this entry point.
Flowly Score
Apr 16 Close
-50%$458.08
Fair Value
$230.00
51
Averageat $458.08
Business Strength9/10
The installed base of surgical systems functions as a toll network on human bodies — every procedure is a royalty, and the biomechanical switching costs embedded in surgeon training are among the most durable moats in all of medtech. ROIC climbing on a larger capital base is the definitive test that this isn't a mature franchise coasting; it's a flywheel that earns more the bigger it gets.
Financial Resilience8/10
OCF matching or exceeding net income every year is proof the income statement isn't a fiction — this is a real cash machine, not an accounting construct. The nearly net-cash balance sheet and the FCF surge as the heavy facility investment cycle normalized reveal an underlying engine with enormous shock-absorption capacity.
Growth & Trajectory7/10
The 2026 deceleration in procedure growth guidance is management being honest about gravity, not a sign of franchise deterioration — the installed base and utilization metrics still point forward. Ion in lung diagnostics and cardiac clearance on da Vinci 5 represent genuine new procedural frontiers, not repackaged volume from existing indications.
Valuation2/10at $493.56
Every DCF scenario that employs growth rates grounded in the physical world — including an optimistic one that would constitute one of the greatest sustained compounding runs in corporate history — yields a fair value well below current prices; the market is pricing not just this platform's dominance but the perfect execution of every optionality bet simultaneously. At an earnings yield under two percent, the investor takes all the downside of a high-quality business at a price that leaves no room for the unexpected.
Risk4/10
J&J's Ottava system arriving into precisely the high-volume soft tissue procedures where da Vinci's economics are most entrenched is the specific threat that could force competitive procurement conversations for the first time in a generation — and J&J doesn't need to build distribution from zero. The valuation itself compounds every other risk: a business priced for perpetual outperformance turns a manageable competitive setback into a catastrophic multiple contraction.
The quality case here is about as clean as it gets in public markets: a procedure-driven annuity model locked in by biomechanical switching costs, ROIC expanding on a growing capital base, and a management team that has resisted the acquisition addiction that eventually hollows out most device franchises. The cash generation is real — confirmed year after year by operating cash flow that shadows reported income. But quality and price are entirely separate conversations, and this market has spent years refusing to separate them. Every defensible FCF scenario, even one requiring sustained growth that few businesses in history have achieved, implies the stock is materially overvalued today. The investor buying here is not buying a margin of safety — they are selling one. The trajectory of the business itself is genuinely interesting. Ion's early bronchoscopy momentum is not a feature in the current financial statements — it is a small but real option on a diagnostics platform that could compound independently of the surgical installed base. The cardiac clearance on da Vinci 5, the XiR refurbished system opening ASCs and international markets at lower price points, and the MyIntuitive+ digital subscription transitioning to paid — these are the early scaffolding of a second-generation platform strategy, not incremental product refreshes. The 2026 procedure growth deceleration to the low-to-mid teens is honest guidance on a maturing penetration curve, not a harbinger of structural decline. The single most specific risk is J&J's Ottava system gaining clinical traction in soft tissue general surgery — the exact high-volume, high-margin procedures where da Vinci's dominance is most economically valuable and where ISRG has the most to lose. Unlike startup competitors, J&J walks into hospital procurement conversations with existing cardiac and orthopedic relationships, a global service infrastructure, and the institutional credibility to survive a multi-year installed-base ramp. If hospitals begin running genuine competitive tenders for robotic surgery rather than reflexively reordering da Vinci systems, the pricing power embedded in current multiples disappears before the earnings impact registers — and at seventy-plus times earnings, there is no cushion for that conversation to begin.